Wall Street analysts expect that Ritter Pharmaceuticals Inc (NASDAQ:RTTR) will announce earnings per share (EPS) of ($0.05) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Ritter Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Ritter Pharmaceuticals posted earnings per share of ($0.74) during the same quarter last year, which indicates a positive year-over-year growth rate of 93.2%. The company is scheduled to report its next quarterly earnings results on Monday, February 26th.

On average, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($0.39) per share for the current fiscal year, with EPS estimates ranging from ($0.42) to ($0.35). For the next financial year, analysts anticipate that the business will report earnings of ($0.30) per share, with EPS estimates ranging from ($0.40) to ($0.20). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Ritter Pharmaceuticals.

A number of analysts recently commented on the stock. Zacks Investment Research downgraded shares of Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. ValuEngine upgraded shares of Ritter Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright dropped their target price on shares of Ritter Pharmaceuticals from $7.00 to $1.50 and set a “buy” rating on the stock in a report on Monday, October 23rd. Finally, Roth Capital set a $2.00 target price on shares of Ritter Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, October 23rd. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. Ritter Pharmaceuticals currently has an average rating of “Hold” and an average target price of $2.10.

Shares of Ritter Pharmaceuticals (NASDAQ RTTR) opened at $0.32 on Thursday. Ritter Pharmaceuticals has a fifty-two week low of $0.27 and a fifty-two week high of $3.42. The company has a market cap of $14.75, a P/E ratio of -0.28 and a beta of 0.53.

An institutional investor recently bought a new position in Ritter Pharmaceuticals stock. Susquehanna International Group LLP bought a new position in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 2,222,522 shares of the biotechnology company’s stock, valued at approximately $778,000. Susquehanna International Group LLP owned approximately 4.49% of Ritter Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 33.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Ritter Pharmaceuticals Inc (RTTR) to Post -$0.05 EPS” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://theolympiareport.com/2018/02/15/zacks-brokerages-anticipate-ritter-pharmaceuticals-inc-rttr-to-post-0-05-eps.html.

Ritter Pharmaceuticals Company Profile

Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.